Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of BI 1819479 in healthy Japanese males
jRCT2071220026Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD) and systemic sclerosis (SSc) comparing BI 1819479 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Aug 2022; status: active, not recruiting.
02
Drugs
BI1819479
03
Conditions
idiopathic pulmonary fibrosis (IPF)interstitial lung disease (ILD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2071220026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220026.